Elicio Therapeutics, Inc. (ELTX)
2.98
-0.06
(-1.97%)
USD |
NASDAQ |
Aug 24, 16:00
2.98
0.00 (0.00%)
After-Hours: 20:00
Elicio Therapeutics Enterprise Value : 55.93M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 55.93M |
| August 21, 2026 | 57.25M |
| August 20, 2026 | 58.02M |
| August 19, 2026 | 59.22M |
| August 18, 2026 | 58.78M |
| August 17, 2026 | 56.81M |
| August 14, 2026 | 58.34M |
| August 13, 2026 | 59.66M |
| August 12, 2026 | 57.69M |
| August 11, 2026 | 57.03M |
| August 10, 2026 | 58.56M |
| August 07, 2026 | 60.53M |
| August 06, 2026 | 59.44M |
| August 05, 2026 | 60.53M |
| August 04, 2026 | 59.88M |
| August 03, 2026 | 53.31M |
| July 31, 2026 | 51.99M |
| July 30, 2026 | 54.40M |
| July 29, 2026 | 53.96M |
| July 28, 2026 | 55.28M |
| July 27, 2026 | 56.37M |
| July 24, 2026 | 56.37M |
| July 23, 2026 | 59.66M |
| July 22, 2026 | 59.00M |
| July 21, 2026 | 58.12M |
| Date | Value |
|---|---|
| July 20, 2026 | 57.25M |
| July 17, 2026 | 58.78M |
| July 16, 2026 | 60.75M |
| July 15, 2026 | 57.25M |
| July 14, 2026 | 58.78M |
| July 13, 2026 | 62.72M |
| July 10, 2026 | 66.89M |
| July 09, 2026 | 67.10M |
| July 08, 2026 | 67.10M |
| July 07, 2026 | 51.99M |
| July 06, 2026 | 62.83M |
| July 02, 2026 | 61.19M |
| July 01, 2026 | 103.24M |
| June 30, 2026 | 76.30M |
| June 29, 2026 | 73.95M |
| June 26, 2026 | 73.95M |
| June 25, 2026 | 69.29M |
| June 24, 2026 | 73.58M |
| June 23, 2026 | 76.00M |
| June 22, 2026 | 76.56M |
| June 18, 2026 | 71.16M |
| June 17, 2026 | 87.19M |
| June 16, 2026 | 50.84M |
| June 15, 2026 | 75.44M |
| June 12, 2026 | 276.19M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Precigen, Inc. | 2.627B |
| Agenus, Inc. | 591.52M |
| Amgen, Inc. | 283.25B |
| Anika Therapeutics, Inc. | 272.43M |
| BioCryst Pharmaceuticals, Inc. | 2.955B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.217M |
| Total Expenses (Quarterly) | 8.217M |
| EPS Diluted (Quarterly) | -0.427 |
| Earnings Yield | -70.93% |
| Normalized Earnings Yield | -71.81 |